Vol 10, No 2 (2019)
Case report
Published online: 2019-10-16

open access

Page views 486
Article views/downloads 221
Get Citation

Connect on Social Media

Connect on Social Media

Treatment efficacy with brentuximab vedotin in the third-line therapy of primary refractory systemic anaplastic large cell lymphoma ALK(–)

Beata Kania-Zembaczyńska1
DOI: 10.5603/Hem.2019.0021
Hematologia 2019;10(2):105-109.

Abstract

Anaplastic large cell lymphoma (ALCL) is rare hematological malignancy and subtype of mature T-cell lymphoma. Most patients with diagnosed systemic ALCL (sALCL) respond to common first-line chemotherapy based on antracycline (CHOP [doxorubicin, vincristine, prednisone], or CHOEP [doxorubicin, vincristine, etoposide, prednisone]). Long-term treatment results depends on a subtype and other prognostic factors. About 40–65% patients with ALCL ALK(–) develop reccurent disease. High-dose chemotherapy and autologous hematopoietic stem cell trasplantation improve outcome in this group of patients. Brentuximab vedotin has shown efficacy with relapsed sALCL and enable gaining objective respones in 86% of cases.

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice